tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Hemolysis D006461 131 associated lipids
Uremia D014511 33 associated lipids
Colitis, Ulcerative D003093 24 associated lipids
Stomach Ulcer D013276 75 associated lipids
Kidney Failure, Chronic D007676 51 associated lipids
Nocardia Infections D009617 6 associated lipids
Diarrhea D003967 32 associated lipids
Diabetes Mellitus D003920 90 associated lipids
Graft Occlusion, Vascular D006083 11 associated lipids
Hypercalcemia D006934 13 associated lipids
Neovascularization, Pathologic D009389 39 associated lipids
Adenocarcinoma D000230 166 associated lipids
Dermatitis, Contact D003877 59 associated lipids
Bacterial Infections D001424 21 associated lipids
Pain D010146 64 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Lupus Erythematosus, Systemic D008180 43 associated lipids
Genital Diseases, Female D005831 7 associated lipids
Mouth Diseases D009059 5 associated lipids
Meningococcal Infections D008589 3 associated lipids
Lung Diseases D008171 37 associated lipids
Lung Neoplasms D008175 171 associated lipids
Mycobacterium Infections D009164 7 associated lipids
Sarcoidosis D012507 13 associated lipids
Hepatolenticular Degeneration D006527 3 associated lipids
Hyperglycemia D006943 21 associated lipids
Carcinoma, Squamous Cell D002294 14 associated lipids
Skin Neoplasms D012878 12 associated lipids
Burns D002056 34 associated lipids
Inflammation D007249 119 associated lipids
Inflammatory Bowel Diseases D015212 9 associated lipids
Reperfusion Injury D015427 65 associated lipids
Colitis D003092 69 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Fatty Liver D005234 48 associated lipids
Cataract D002386 34 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Body Weight D001835 333 associated lipids
Edema D004487 152 associated lipids
Precancerous Conditions D011230 48 associated lipids
Postoperative Complications D011183 5 associated lipids
Arthritis D001168 41 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Surgical Wound Infection D013530 7 associated lipids
Neoplasm Recurrence, Local D009364 5 associated lipids
Osteonecrosis D010020 5 associated lipids
Hypotension D007022 41 associated lipids
Acute Kidney Injury D058186 34 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
First International Congress on FK 506. August 21-24, 1991, Pittsburgh, PA. 1991 Transplant. Proc. pmid:1721253
Goto T et al. FK 506: historical perspectives. 1991 Transplant. Proc. pmid:1721254
Ochiai T et al. Effective and safe use of FK 506: combination treatment with rapamycin or RS-61443 in experimental organ transplantation. 1991 Transplant. Proc. pmid:1721255
Siekierka JJ et al. Potential roles of other FK 506-binding proteins in mediating the effects of FK 506. 1991 Transplant. Proc. pmid:1721256
Farghali H et al. FK 506 modulates D-galactosamine-induced hepatitis in rats. 1991 Transplant. Proc. pmid:1721285
Müller MK et al. Inhibition of insulin release by FK 506 and its prevention by rioprostil, a stable prostaglandin E1 analogue. 1991 Transplant. Proc. pmid:1721286
Francavilla A et al. The effects of FK 506, cyclosporine, and rapamycin on liver growth in vitro and in vivo. 1991 Transplant. Proc. pmid:1721287
Blanc P et al. Antiproliferative effect of FK 506 and cyclosporine on adult human hepatocytes in culture. 1991 Transplant. Proc. pmid:1721288
Jiang H et al. Combined immunosuppressive effect of FK 506 and other immunosuppressive agents on PHA- and CD3-stimulated human lymphocyte proliferation in vitro. 1991 Transplant. Proc. pmid:1721317
Yagihashi A et al. The effect of FK 506 on peripheral blood T-lymphocyte subsets in orthotopic liver transplant patients. 1991 Transplant. Proc. pmid:1721318
Woo J et al. Effects of FK 506, mycophenolic acid, and bredinin on OKT-3-, PMA-, and alloantigen-induced activation molecule expression on cultured CD4+ and CD8+ human lymphocytes. 1991 Transplant. Proc. pmid:1721319
Chen-Woan M et al. Diminished lymphocyte growth from endomyocardial biopsies from cardiac transplant patients on FK 506 immunosuppression. 1991 Transplant. Proc. pmid:1721320
Morel P et al. Liver retransplantation in adults: overall results and determinant factors affecting the outcome. 1991 Transplant. Proc. pmid:1721349
Felser I et al. Changes in quality of life following conversion from CyA to FK 506 in orthotopic liver transplant patients. 1991 Transplant. Proc. pmid:1721350
Schreiber SL Chemistry and biology of the immunophilins and their immunosuppressive ligands. 1991 Science pmid:1702904
Alessiani M et al. CMV infection in liver transplantation under cyclosporine or FK 506 immunosuppression. 1991 Transplant. Proc. pmid:1721351
Wasik M et al. Effect of FK506 versus cyclosporine on human natural and antibody-dependent cytotoxicity reactions in vitro. 1991 Transplantation pmid:1702910
Green M et al. Infectious complications of pediatric liver transplantation under FK 506. 1991 Transplant. Proc. pmid:1721352
Carroll PB et al. Effect of the immunosuppressant FK506 on glucose-induced insulin secretion from adult rat islets of Langerhans. 1991 Transplantation pmid:1702911
Yamada K et al. Short-term FK 506-induced morphological changes in rat kidneys. 1991 Transplant. Proc. pmid:1721381
Moutabarrik A et al. FK 506 mechanism of nephrotoxicity: stimulatory effect on endothelin secretion by cultured kidney cells and tubular cell toxicity in vitro. 1991 Transplant. Proc. pmid:1721382
Moutabarrik A et al. In vitro FK 506 kidney tubular cell toxicity. 1991 Transplant. Proc. pmid:1721383
McCauley J et al. Changes in renal function after liver transplantation under FK 506. 1991 Transplant. Proc. pmid:1721385
Wang X et al. Intraportal FK 506 improves intrahepatic islet allograft survival. 1991 Transplant. Proc. pmid:1721412
Ohtsuka S et al. The effect of short-term FK 506 therapy on pancreas transplantation in rats. 1991 Transplant. Proc. pmid:1721413
Yamashita T et al. Prolongation of pancreaticoduodenal allograft survival in rats by treatment with FK 506. 1991 Transplant. Proc. pmid:1721414
Fukuzaki T et al. Induction of tolerance to islet allografts with preoperative donor spleen cell injection and a short course of FK 506 treatment. 1991 Transplant. Proc. pmid:1721415
Tzakis AG et al. FK 506 rescue in chronic graft-versus-host-disease after bone marrow transplantation. 1991 Transplant. Proc. pmid:1721416
Lin CS et al. FK-506 and cyclosporin A inhibit highly similar signal transduction pathways in human T lymphocytes. 1991 Cell. Immunol. pmid:1707760
Vincent SH et al. Effects of the immunosuppressant FK-506 and its analog FK-520 on hepatic and renal cytochrome P450 mixed-function oxidase. 1991 Biochem. Pharmacol. pmid:1708254
Kitahara S et al. Lymphoproliferative disorders after FK 506. 1991 Lancet pmid:1708846
Holechek MJ Medication review: FK 506. 1991 ANNA J pmid:1708982
Wada H et al. Dose response to FK 506 in canine lung transplantation. 1991 Transplant. Proc. pmid:1721444
Lin CY et al. Effects of FK 506 on the biochemical markers in canine lung allograft rejection. 1991 Transplant. Proc. pmid:1721445
Propper DJ et al. Evidence that FK 506 may abrogate suppressor cell activity induced by blood transfusion. 1991 Transplant. Proc. pmid:1721446
Fabrega AJ et al. FK 506 enhances the beneficial effects of donor-specific blood transfusion on allograft survival in rats. 1991 Transplant. Proc. pmid:1721447
Kawano K et al. A protective effect of FK506 in ischemically injured rat livers. 1991 Transplantation pmid:1713362
Armitage JM et al. Preliminary experience with FK506 in thoracic transplantation. 1991 Transplantation pmid:1713363
Lorber MI et al. A comparison of in vivo responses to cyclosporine, FK506, and rapamycin following allogeneic immune challenge. 1991 Transplantation pmid:1713364
Abu-Elmagd K et al. The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. 1991 Transplantation pmid:1713365
Burres NS et al. Dunaimycins, a new complex of spiroketal 24-membered macrolides with immunosuppressive activity. III. Immunosuppressive activities of dunaimycins. 1991 J. Antibiot. pmid:1723403
Nielsen JB et al. Biosynthesis of the immunosuppressant immunomycin: the enzymology of pipecolate incorporation. 1991 Biochemistry pmid:2043618
McKeon F When worlds collide: immunosuppressants meet protein phosphatases. 1991 Cell pmid:1716181
Petros AM et al. NMR studies of an FK-506 analogue, [U-13C]ascomycin, bound to FKBP: conformation and regions of ascomycin involved in binding. 1991 J. Med. Chem. pmid:1716684
FK 506--an investigational immunosuppressant. 1991 Med Lett Drugs Ther pmid:1716722
Ochiai T et al. [Immunosuppressive agents--advances of the developmental studies and the mode of action]. 1991 Nippon Rinsho pmid:1715926
Ricordi C et al. In vivo effect of FK506 on human pancreatic islets. 1991 Transplantation pmid:1716797
Takahara S et al. Survival of cardiac allograft in highly sensitized and nonsensitized rats treated with FK506. 1991 J Clin Lab Immunol pmid:1726566
Stötter H and Lotze MT Human lymphokine-activated killer cell activity. Role of IL-2, IL-4, and IL-7. 1991 Arch Surg pmid:1726819
Karlsson H and Nässberger L FK506 lacks the ability to inhibit expression of interleukin-2 receptor beta-chain on human lymphocytes. 1991 J Clin Lab Immunol pmid:1726895